Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial

医学 改良兰金量表 脑出血 格拉斯哥昏迷指数 随机对照试验 人口 溶栓 意向治疗分析 冲程(发动机) 外科 麻醉 临床终点 内科学 缺血性中风 心肌梗塞 缺血 工程类 环境卫生 机械工程
作者
Daniel F. Hanley,Richard E. Thompson,Michael Rosenblum,Gayane Yenokyan,Karen Lane,Nichol A. McBee,Steven W Mayo,Amanda J. Bistran-Hall,Dheeraj Gandhi,W. Andrew Mould,Natalie L. Ullman,Hasan Ali,Juan Ricardo Carhuapoma,Carlos S. Kase,Kennedy R. Lees,Jesse Dawson,Alastair Wilson,Joshua Betz,Elizabeth A. Sugar,Yi Hao
出处
期刊:The Lancet [Elsevier BV]
卷期号:393 (10175): 1021-1032 被引量:1009
标识
DOI:10.1016/s0140-6736(19)30195-3
摘要

Acute stroke due to supratentorial intracerebral haemorrhage is associated with high morbidity and mortality. Open craniotomy haematoma evacuation has not been found to have any benefit in large randomised trials. We assessed whether minimally invasive catheter evacuation followed by thrombolysis (MISTIE), with the aim of decreasing clot size to 15 mL or less, would improve functional outcome in patients with intracerebral haemorrhage.MISTIE III was an open-label, blinded endpoint, phase 3 trial done at 78 hospitals in the USA, Canada, Europe, Australia, and Asia. We enrolled patients aged 18 years or older with spontaneous, non-traumatic, supratentorial intracerebral haemorrhage of 30 mL or more. We used a computer-generated number sequence with a block size of four or six to centrally randomise patients to image-guided MISTIE treatment (1·0 mg alteplase every 8 h for up to nine doses) or standard medical care. Primary outcome was good functional outcome, defined as the proportion of patients who achieved a modified Rankin Scale (mRS) score of 0-3 at 365 days, adjusted for group differences in prespecified baseline covariates (stability intracerebral haemorrhage size, age, Glasgow Coma Scale, stability intraventricular haemorrhage size, and clot location). Analysis of the primary efficacy outcome was done in the modified intention-to-treat (mITT) population, which included all eligible, randomly assigned patients who were exposed to treatment. All randomly assigned patients were included in the safety analysis. This study is registered with ClinicalTrials.gov, number NCT01827046.Between Dec 30, 2013, and Aug 15, 2017, 506 patients were randomly allocated: 255 (50%) to the MISTIE group and 251 (50%) to standard medical care. 499 patients (n=250 in the MISTIE group; n=249 in the standard medical care group) received treatment and were included in the mITT analysis set. The mITT primary adjusted efficacy analysis estimated that 45% of patients in the MISTIE group and 41% patients in the standard medical care group had achieved an mRS score of 0-3 at 365 days (adjusted risk difference 4% [95% CI -4 to 12]; p=0·33). Sensitivity analyses of 365-day mRS using generalised ordered logistic regression models adjusted for baseline variables showed that the estimated odds ratios comparing MISTIE with standard medical care for mRS scores higher than 5 versus 5 or less, higher than 4 versus 4 or less, higher than 3 versus 3 or less, and higher than 2 versus 2 or less were 0·60 (p=0·03), 0·84 (p=0·42), 0·87 (p=0·49), and 0·82 (p=0·44), respectively. At 7 days, two (1%) of 255 patients in the MISTIE group and ten (4%) of 251 patients in the standard medical care group had died (p=0·02) and at 30 days, 24 (9%) patients in the MISTIE group and 37 (15%) patients in the standard medical care group had died (p=0·07). The number of patients with symptomatic bleeding and brain bacterial infections was similar between the MISTIE and standard medical care groups (six [2%] of 255 patients vs three [1%] of 251 patients; p=0·33 for symptomatic bleeding; two [1%] of 255 patients vs 0 [0%] of 251 patients; p=0·16 for brain bacterial infections). At 30 days, 76 (30%) of 255 patients in the MISTIE group and 84 (33%) of 251 patients in the standard medical care group had one or more serious adverse event, and the difference in number of serious adverse events between the groups was statistically significant (p=0·012).For moderate to large intracerebral haemorrhage, MISTIE did not improve the proportion of patients who achieved a good response 365 days after intracerebral haemorrhage. The procedure was safely adopted by our sample of surgeons.National Institute of Neurological Disorders and Stroke and Genentech.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei的应助被theverve采纳,获得10
2秒前
2秒前
Meo完成签到,获得积分20
2秒前
aaa发布了新的文献求助10
2秒前
尊敬元芹完成签到,获得积分10
3秒前
天天快乐的应助被雅米采纳,获得10
3秒前
PYF8086完成签到,获得积分10
4秒前
幽默的小松鼠完成签到,获得积分10
5秒前
5秒前
林佳明发布了新的文献求助60
6秒前
绳网用户17117496完成签到,获得积分10
6秒前
6秒前
gaojiani完成签到,获得积分10
7秒前
思源的应助被于66采纳,获得10
7秒前
7秒前
mahuahua发布了新的文献求助60
7秒前
乐乐的应助被青山采纳,获得10
8秒前
8秒前
christina完成签到,获得积分10
8秒前
8秒前
852的应助被sssshhh采纳,获得10
8秒前
9秒前
荷包蛋不吃猫完成签到 ,获得积分10
9秒前
还读书呢发布了新的文献求助200
10秒前
泥娃娃完成签到,获得积分10
10秒前
gaojiani发布了新的文献求助10
11秒前
大模型的应助被谨慎的秋烟采纳,获得10
11秒前
跳跃的数据线完成签到 ,获得积分10
12秒前
13秒前
13秒前
13秒前
鸥羡发布了新的文献求助10
13秒前
kalah完成签到,获得积分10
13秒前
LWW发布了新的文献求助10
14秒前
小蘑菇的应助被开朗紫采纳,获得10
15秒前
rururu完成签到,获得积分10
16秒前
思源的应助被假发君采纳,获得10
17秒前
aki完成签到,获得积分10
17秒前
盈虚者发布了新的文献求助10
17秒前
羊羊羊完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158056
求助须知:如何正确求助?哪些是违规求助? 9553944
关于积分的说明 21716733
捐赠科研通 7747388
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551676
邀请新用户注册赠送积分活动 2471038